Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index; 31 of the 76 sources its claims cite were checked for support.
Abstract
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune dysregulation, present before CAR T-cell therapy, was associated with treatment failure. Tumor expression of interferon (IFN) signaling, high blood levels of monocytic myeloid-derived suppressor cells (M-MDSCs), and high blood interleukin-6 and ferritin levels were each associated with a lack of durable response. Similar to other cancers, we found that in LBCL tumors, IFN signaling is associated with the expression of multiple checkpoint ligands, including programmed cell death–ligand 1, and these were higher in patients who lacked durable responses to CAR-T therapy. Moreover, tumor IFN signaling and blood M-MDSCs associated with decreased axi-cel expansion. Finally, patients with high tumor burden had higher immune dysregulation with increased serum inflammatory markers and tumor IFN signaling. These data support that immune dysregulation in LBCL promotes axi-cel resistance via multiple mechanistic programs: insufficient axi-cel expansion associated with both circulating M-MDSC and tumor IFN signaling, which also gives rise to expression of immune checkpoint ligands.
Overview
CoChat Summary
TL;DR
In patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), pretherapy immune dysregulation—tumor interferon signaling, circulating monocytic myeloid-derived suppressor cells (M-MDSCs), and elevated inflammatory markers—was associated with lack of durable response. Tumor interferon signaling and M-MDSCs also associated with decreased axi-cel expansion, and high tumor burden was linked to greater systemic and tumor inflammation.
Key findings
- Among 105 axi-cel-treated patients, lack of durable response was associated with tumor interferon signaling, high blood M-MDSCs, and high blood interleukin-6 and ferritin levels.
- Pretreatment tumor biopsies showed higher malignant B-cell PD-L1 and MHC II in nondurable responders; RNA data showed enrichment of the tumor ISG.RS interferon signature in nondurable responders and the T-cell IFNG.GS signature in durable responders. Macrophage-associated genes CD163 (3.4-fold; P = .02) and Siglec-1 (2.9-fold; P < .001) were higher at baseline in nondurable responders.
- Median peak axi-cel levels were 10-fold higher in durable responders than nondurable responders (P = .01); patients with high baseline M-MDSCs (greater than median; 250 cells per μL) had 4-fold lower peak axi-cel expansion (P = .02), and tumor interferon signaling genes were highly expressed in patients with poor axi-cel expansion.
- High tumor burden (>150 mL metabolic tumor volume) was associated with higher ferritin, IL-6, IL-15, TNF-α, and ANG2/ANG1; in public NCICCR LBCL data, high ISG.RS was associated with multiple T-cell inhibitory ligands and with SOCS1 and KLHL6 mutations.
Methods
- Observational study of samples from 105 patients treated with axi-cel: 85 received standard-of-care therapy, 14 as part of a clinical trial, and 6 under the ZUMA-9 expanded access trial. Durable responders remained in remission with a minimum follow-up of 6 months after infusion; nondurable responders died of any cause or relapsed.
- Assays included multiplex immunofluorescence for CD19, CD20, CD3, PD-L1, MHC I, and MHC II (n = 26); NanoString IO360 gene expression (n = 35); RNA-sequencing (n = 18); flow cytometry for M-MDSCs; quantitative polymerase chain reaction for axi-cel expansion; and serum cytokine, ferritin, and CRP measurements.
- Analyses compared durable vs nondurable responders, used gene set enrichment and GSVA for interferon signatures, assessed correlations, and interrogated the public NCICCR-DLBCL data set for ISG.RS-associated features.
Limitations
- Paper-stated: the study was observational and therefore limited to describing associations rather than concluding causal links.
- Paper-stated: multivariable modeling of clinical outcomes using tumor genetics, peripheral blood cytokines, metabolic tumor volume, tumor microenvironment characteristics, and circulating immune subsets would be ideal, but the authors could not analyze every biomarker in each patient because of sample-collection constraints.
- Evident from the text: several assay-specific sample sizes were small (e.g., multiplex immunofluorescence n = 26, NanoString n = 35, RNA-sequencing n = 18, M-MDSC/TME overlap n = 11), and patients were treated across standard-of-care, clinical trial, and expanded-access settings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 1 Not valid · 18 Not checked · 105 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“patients with lymphoma have high levels of circulating myeloid-derived suppressor cells (MDSCs) compared with healthy control subjects”
What the sources say
- Disputedcites [16] Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872-881. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results distinguish MDSCs from the CD14+HLA-DRlow/− suppressive monocytes studied in lymphoma patients. They report that circulating MDSCs were infrequent and not significantly higher than in healthy controls, contrary to the claim. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [20] Azzaoui I, Uhel F, Rossille D, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128(8):1081-1092. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The section “MDSCs are expanded in peripheral blood of DLBCL patients” reports significantly higher circulating MDSC counts in patients with diffuse large B-cell lymphoma than in healthy donors. The claim says “patients with lymphoma” generally, while this study’s comparison is limited to that lymphoma subtype; the indexed passage provides no page number. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients with active disease experience systemic immune dysregulation detectable in peripheral blood and characterized by elevated cytokines, altered myeloid cell populations, and T-cell deficits.”
What the sources say
- Not checked yetcites [14] Porrata LF. Beware of the neutrophil/lymphocyte ratio in diffuse large B-cell lymphoma. Leuk Lymphoma. 2019;60(14):3345-3346. [DOI] [PubMed] [Google Scholar] source
- Partly supportedcites [15] Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010;85(11):896-899. [DOI] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The discussion (p. 897) links a high blood neutrophil-to-lymphocyte ratio in patients with diffuse large B-cell lymphoma to inflammation and suggests that immune suppression could lower the absolute lymphocyte count. It does not establish elevated cytokines, altered myeloid-cell populations, or T-cell deficits in patients with active disease; the authors say the proposed mechanism needs prospective study. (LLM, conf=0.86)
- Partly supportedcites [16] Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood. 2011;117(3):872-881. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results and Discussion describe systemic immune suppression in peripheral blood, immunosuppressive monocytes, and reduced T-cell counts or function in patients with B-cell non-Hodgkin lymphoma. The Results report elevated VEGF, but not significantly elevated IL-6, IL-10, CCL-2, or TGF-β; the broad claim of elevated cytokines is therefore not supported. The paper also associates the monocyte phenotype with more aggressive disease rather than establishing the full pattern specifically for all patients with active disease. (LLM, conf=0.88)
- Partly supportedcites [17] Charbonneau B, Maurer MJ, Ansell SM, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine. 2012;60(3):882-889. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Results §3.2 reports elevated serum levels of several cytokines in patients with follicular lymphoma or diffuse large B-cell lymphoma compared with controls. Methods §2.2 describes serum cytokine testing, not measurements of myeloid cell populations or T-cell deficits; the paper therefore does not support those parts of the claim. (LLM, conf=0.90)
- Not checked yetcites [18] Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol. 1995;13(3):575-582. [DOI] [PubMed] [Google Scholar] source
- Not checked yetcites [19] Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med. 1997;127(3):186-194. [DOI] [PubMed] [Google Scholar] source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the pivotal ZUMA-1 trial, the degree of early axi-cel expansion in the peripheral blood associated with a DR.”
What the sources say
- Supportedcites [1] Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. [DOI] [PMC free article] [PubMed] [Google Scholar] source
The Results report that an ongoing response at 24 months was associated with higher peak CAR T-cell concentrations and greater area under the curve during the first 28 days after axi-cel infusion. The Methods (Procedures; page not available) specify that CAR T-cell concentrations were measured in blood. This supports the claim that greater early peripheral-blood expansion was associated with a durable response. (LLM, conf=0.94)
- Partly supportedcites [2] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
The Results (Biomarkers; page not provided) report that early axi-cel expansion in peripheral blood was significantly associated with response. They do not establish an association specifically with durable response (DR); the Discussion describes the association as one with objective response. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When tumors express a gene signature (ISG.RS) consisting of genes coordinately activated by multiple types of IFN, a multigenic therapy resistance program is activated.”
What the sources say
- Could not verifycites [2] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Our copy of the ZUMA-1 trial (Neelapu et al. 2017, NEJM) addresses axi-cel efficacy, CAR T-cell expansion, cytokine-release syndrome and neurologic events; no passage mentions an interferon-stimulated gene signature (ISG.RS), interferon types, or a multigenic therapy-resistance program. Searched: 'ISG.RS interferon-stimulated gene signature therapy resistance', 'interferon gene expression tumor resistance program multigenic', and 'interferon signature gene expression tumor cell-of-origin resistance to therapy' — the top hits were the Results/Biomarkers and Discussion sections on serum cytokines (IL-6, -10, -15, -2Rα, GM-CSF, ferritin) and the reference list. The closest gene-expression content is the Methods (End Points and Assessments) noting cell-of-origin subtype by the NanoString Lymphoma Subtyping Test, which says nothing about interferon-driven resistance. Our copy neither supports nor contradicts the claim, and it credits the point to no other work. (LLM, conf=0.75)
- Partly supportedcites [24] Benci JL, Xu B, Qiu Y, et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell. 2016;167(6):1540-1554.e12. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Our copy supports the core idea: tumor IFN signaling (type I and II, via STAT1) drives a 'multigenic resistance program' of TCIR ligands plus ISGs, which the authors define as IDILS (PDL1, TNFRSF14, LGALS9, MHCII, CD86, IFIT1, MX1) and which associates with clinical progression after anti-PD1 (RESULTS 'A Multigenic Resistance Program of TCIR Ligands and ISGs'; RESULTS 'High Expression of ISGs Can Associate with Clinical Progression After Anti-PD1'; DISCUSSION). However, the term 'ISG.RS' never appears in our copy (no exact-phrase hits; searches for 'ISG.RS' and 'coordinately activated' returned only semantic neighbours), and the ISG component is explicitly credited to another work — the 'ISGs that we previously described to be robustly expressed across human cancers (Weichselbaum et al., 2008)'. The claim's signature name and its framing that the signature itself activates resistance (rather than IFN/STAT1 signaling driving IDILS, with ISGs as correlative biomarkers) are therefore not stated by this paper. (LLM, conf=0.70)
- Partly supportedcites [54] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-377. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Our copy supports only part of this: the main text (Abstract/Results, Fig. 1g, Extended Data Fig. 2e) reports that transcriptomic profiling of resistant tumors (Res 499/177, Res 237) defined a multigenic RT + anti-CTLA4 'resistance gene signature' that includes PD-L1 together with interferon stimulated genes, and that PD-L1 was co-expressed with that signature in a metastatic melanoma patient cohort. However, the paper never names or defines a signature 'ISG.RS', never states that its genes are coordinately activated by multiple types of IFN (IFN-gamma is used only experimentally to induce PD-L1, and type I IFN is credited to separate LCMV works, refs 10-11), and it bounds the resistance program to resistance against radiation plus CTLA4 blockade rather than 'therapy resistance' generally. The claim's causal framing ('when tumors express ... a resistance program is activated') also exceeds the correlative gene-profiling evidence the paper presents, and the paper instead identifies elevated PD-L1 as the dominant resistance mechanism, with ISGs described only as genes that 'may promote immune suppression through PD-L1'. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These results suggest that a subset of LBCLs rely on tumor IFN signaling to mediate T-cell exhaustion and defend against antitumor immunity.23”
What the sources say
- Partly supportedcites [23] de Charette M, Houot R. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica. 2018;103(8):1256-1268. [DOI] [PMC free article] [PubMed] [Google Scholar] sourceExperimental — accuracy not yet measured
Our copy of de Charette et al. 2018 supports the surrounding elements of the claim but not its causal mechanism: the 'Defend' section (Inhibition / killing of immune cells) states that a subset of large B-cell lymphomas — DLBCL, more often ABC than GC (PD-L1 36% / 4% ; PD-L2 60% / 26%), PMBL (71%) and immune-privileged DLBCL with 9p24 alterations — inhibit T cells through PD-L1/PD-L2, LAG-3/MHC-II and HLA-G, and the Immunosuppressive microenvironment > Cytokines passage (p. n/a) describes an exhausted CTL phenotype (high PD-1 and TIM-3) in B-cell NHL. However, that exhaustion is attributed to tumor/microenvironment TGF-β (ref 123), not to tumor interferon signalling: five searches of our full-text copy (interferon, IFN, IFN-γ/type I IFN, JAK-STAT, tumor IFN signaling) returned no passage stating that tumor IFN signaling mediates T-cell exhaustion in LBCL — the only JAK reference is JAK2 within the 9p24 amplicon driving PD-L1/PD-L2 transcription. So the IFN-signaling element of the sentence is not supported by this source. (LLM, conf=0.68)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
78 more claims · 2 with their cited sources checked
Create a free account to see all 139 claims and to verify the 45 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The loss of antitumor efficacy has been attributed to CAR-T cell exhaustion in the tumor microenvironment17,18, or, to a lesser extent, immune evasion of malignant cells with loss of tumor surface antigen expression19.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results
“We compared TME gene expression according to NanoString in patients with a high ferritin level (>1000 ng/mL; n = 8) vs patients with lower ferritin levels (<1000 ng/mL; n = 28).”
§ Results
“We therefore used a NanoString limited gene expression panel enriched for genes of the TME on pretreatment biopsy specimens (n = 35).”
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,528
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationGenetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationInterferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Garcia-Diaz, A., Shin, D. S., Moreno, B. H., Saco, J., Escuin-Ordinas, H., Rodriguez, G. A., Zaretsky, J. M., Sun, L., Hugo, W., Wang, X., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.031 · Cited by 1,942
Self-citationChapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A., Lawrence, M. S., Roemer, M. G. M., Li, A. J., Ziepert, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0016-8 · Cited by 1,941
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
Cited by
Items 101–200 of 306
Dave, H., Terpilowski, M., Mai, M., Toner, K., Grant, M., Stanojevic, M., Lazarski, C. A., Shibli, A., Bien, S. A., Maglo, P. Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005343 · Cited by 19
“evidence of exhaustion and myeloid-derived suppressor cells that are known to impair T-cell expansion and function.(30-32) The 2 patients who were recollected after exposure to nivolumab had successful products generated, which suggests that nivolumab priming before collection could be used as a future strategy to gen…”
BackgroundWinkelmann, M., Raj, S. S., Jain, M. D., Iacoboni, G., Müller, F., Hansmann, L., Corona, M., Luna, A., Jhaveri, K. S., Shah, G. L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01338-1 · Cited by 22
Self-citationFahrmann, J. F., Saini, N. Y., Chia-Chi, C., Irajizad, E., Strati, P., Nair, R. K., Fayad, L., Ahmed, S., Lee, H. J., Iyer, S. P., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100720 · Cited by 19
“A polyamine centric metabolomics liquid biopsy panel has predictive value for response to CAR-T therapy in r/r LBCL.”
BackgroundSelf-citationVoltin, C., Gödel, P., Beckmann, L., Heger, J., Kobe, C., Kutsch, N., Borchmann, P., Dietlein, M., Herrmann, K., Stelljes, M., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000817 · Cited by 20
Wang, H., Yang, F.-C., Yang, C., Liu, Y., Ko, P., Li, C.-J., Tsai, C., Chung, Y., & Chen, N. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00399-x · Cited by 19
Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review
Strati, P., Gregory, T. K., Majhail, N. S., & Jain, N. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00819 · Cited by 22
Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma
Miller, K. C., Hashmi, H., & Rajeeve, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398902 · Cited by 24
Toxicities associated with adoptive cellular therapies
Hansen, D. K., Dam, M., & Faramand, R. G. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101287 · Cited by 19
Self-citationKim, S. J., Yoon, S. E., & Kim, W. S. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.0388 · Cited by 22
“In an evaluation of pretreatment tumor tissues and blood samples of DLBCL patients, tumor expression of interferon signaling and high levels of monocytic myeloid-derived suppressor cells, IL-6, and ferritin were associated with a lack of a durable response [78].”
BackgroundTargeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Lewis, R. I., Stein, A. F. V., & Hallek, M. J. (2024) · Blood · doi:10.1182/blood.2023022861 · Cited by 18
Engineering T cells to survive and thrive in the hostile tumor microenvironment
Kim, G. B., Riley, J. L., & Levine, B. L. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100360 · Cited by 18
Ponzo, M., Drufuca, L., Buracchi, C., Sindoni, M. M., Nucera, S., Bugarin, C., Bason, R., Rossetti, G., Bonnal, R. J. P., Meli, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011768 · Cited by 18
Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
Dreyzin, A., Rankin, A. W., Luciani, K., Gavrilova, T., & Shah, N. N. (2024) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2024.2349738 · Cited by 18
Cortés‐Bullich, A., Perez, A. P., Bachmeier, C. A., Mhaskar, R. S., Chávez, J. C., Shah, B. D., Nishihori, T., Khimani, F., Lazaryan, A., Davila, M. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.05.018 · Cited by 15
Self-citationJallouk, A. P., Gouni, S., Westin, J. R., Feng, L., Mistry, H. E., Steiner, R. E., James, J. G., Noorani, M., Horowitz, S. B., Puebla‐Osorio, N., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281954 · Cited by 16
“is through an increased presence of pro-tumoral macrophages that contribute to an immunosuppressive microenvironment.(10-12) However, it is difficult to determine what role this mechanism plays when residual disease is too small to be detected by PET.”
BackgroundDenlinger, N., Song, N., Zhang, X., Jeon, H., Peterson, C. M., Wang, Y., Reynolds, K., Bolz, R. M., Miao, J., Song, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012073 · Cited by 17
“12-14 However, patients with multiple clinical risk factors can still experience success with CAR19, and patients with low-risk disease still experience failure.”
Hirayama, A. V. V., Wright, J. H., Smythe, K. S., Fiorenza, S., Shaw, A. N., Gauthier, J., Maloney, D. G., Naresh, K. N., Yeung, C. C. S., & Turtle, C. J. (2024) · HemaSphere · doi:10.1002/hem3.142 · Cited by 16
“Nevertheless, our results are consistent with other studies that showed tumor cells expressing PD ‐ L1 13 and macrophages expressing PD ‐ L1, 23 consistent with an anti ‐ inflammatory M2 phenotype, 40,41 were higher in pretreatment biopsies of patients who had worse outcomes after CAR ‐”
BackgroundResultSarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B-cell Lymphoma
Jhaveri, K. S., Thapa, R., Ercan, D., Saha, A., Noble, J. D., Singh, P., Fahrmann, J. F., Saini, N. Y., Wu, R., Dennison, J. B., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3782 · Cited by 18
Self-citationMechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 16
“This highly pro-inflammatory TME may be indirectly evaluated by pre-infusion serum levels of ferritin, IL-6, and CRP [92] Finally, the PD1/PD-L1 axis, overexpressed within the TME and partly driven by IFN-α , IFN-β , and IFN-γ , plays a central role in inducing T-cell anergy through physiological…”
Zhao, K., Ren, C., Tang, D., Zhao, L., Chen, X., Wang, Y., & Xu, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1101769 · Cited by 18
Alderuccio, J. P., dos Reis, I. M., Hamadani, M., Nachiappan, M., Leslom, S., Kahl, B. S., Ai, W. Z., Radford, J. A., Solh, M., Ardeshna, K. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1561 · Cited by 16
Borogovac, A., & Siddiqi, T. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.01.001 · Cited by 14
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma
Luan, D., Valid, O. B., Beyar-Katz, O., Tix, T., Golan-Accav, N., Alhomoud, M., Avigdor, A., Bücklein, V., Cohen, L., Dahi, P. B., et al. (2026) · Blood · doi:10.1182/blood.2025031476 · Cited by 14
Zhang, M., Long, X., Xiao, Y., Jin, J., Chen, C., Meng, J., Liu, W., Liu, A., & Chen, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007790 · Cited by 13
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
Savelli, C. B., Clerico, M., Botto, B., Secreto, C., Cavallo, F., Dellacasa, C. M., Busca, A., Bruno, B., Freilone, R., Cerrano, M., et al. (2023) · Cancers · doi:10.3390/cancers16010046 · Cited by 15
“For instance, interferon signaling boosts the expression of programmed death ligand 1 (PDL-1) on cancer cells, which promotes T-cell exhaustion [25].”
BackgroundCAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms
Kearl, T. J., Furqan, F., & Shah, N. N. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10228-0 · Cited by 16
“Jain et al. found that CAR T-cell expansion and clinical response negatively associated with both tumor interferon signaling and the presence of monocytic myeloid-derived suppressor cells in the peripheral blood of LBCL patients treated with axi-cel ( n = 105) [90].”
Song, F., Tsahouridis, O., Stucchi, S., Walhart, T. A., Mendell, S. E., Hardy, P. B., Axtman, M., Guduru, S. K. R., Gilbert, T. S. K., Graves, L. M., et al. (2025) · Nature Immunology · doi:10.1038/s41590-024-02042-1 · Cited by 13
Borogovac, A., & Siddiqi, T. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2023.100 · Cited by 20
Impacts of ageing on the efficacy of CAR-T cell therapy
Qi, S., Li, J., Gu, X., Zhang, Y., Zhou, W., Wang, F., & Wang, W. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102715 · Cited by 13
The mechanisms and countermeasures for CAR-T cell expansion and persistence deficiency
Bao, Y.-T., Lv, M., Huang, X., & Zhao, X. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217771 · Cited by 14
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
Pelzl, R. J., Benintende, G., Gsottberger, F., Scholz, J. K., Ruebner, M., Yao, H., Wendland, K., Rejeski, K., Altmann, H., Petkovic, S., et al. (2025) · Blood · doi:10.1182/blood.2024027877 · Cited by 14
Tan, J. Y., Low, M. H., Chen, Y., & Lim, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136931 · Cited by 12
“observed that high blood levels of monocytic MDSCs in patients with B cell lymphomas prior to CAR T cell therapy resulted in a lack of durable response [41].”
BackgroundErdogan, E., Yalçın, K., Hemşinlioğlu, C., Sezgin, A., Seyis, U., Kançağı, D. D., Taştan, C., Yurtsever, B., Turan, R. D., Çakırsoy, D., et al. (2022) · Turkish Journal of Hematology · doi:10.4274/tjh.galenos.2022.2022.0193 · Cited by 14
“The mechanism could be explained by challenging the tumor microenvironment and also by immundysregulation induced by a high tumor burden.(24) Although it is known that response rates are not satisfactory in DLBCL, response rates in this study (3 PR for 3 patients) for bulky DLBCL appears acceptable.”
BackgroundZalka, C. V. (2012) · Digital Commons - East Tennessee State University (East Tennessee State University) · Cited by 23
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 14
“51 In multiple myeloma, response rates are high across all subgroups, but patients with unfavourable cytogenetic profiles have a shorter duration of response.”
Phina-Ziebin, X., Bachy, E., Gros, F., Blasi, R. D., Herbaux, C., Bay, J. O., Carras, S., Bories, P., Casasnovas, O., Jardin, F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024014732 · Cited by 11
How I treat HLH-like toxicities after immune effector cell therapy
Johnson, W. T., McNerney, K. O., Frank, M. J., & Shah, N. N. (2026) · Blood · doi:10.1182/blood.2025032352 · Cited by 11
Are we there yet? The road to faster and more efficient CAR T cell manufacturing
Matos, L. N., Costa, M. S., Serra, M., & Costa, M. H. G. (2026) · Journal of Biological Engineering · doi:10.1186/s13036-026-00666-5 · Cited by 12
“High tumor burden drives T cell exhaustion and is often accompanied by systemic inflammation, with elevated levels of IL-6 and TNF-α, and high levels of IFN signalling associated with reduced CAR T cell expansion and a lack of durable responses [75].”
Jain, M. D., & Spiegel, J. Y. (2021) · eJHaem · doi:10.1002/jha2.357 · Cited by 10
“However, we found that systemic inflammationandanunfavorable cytokineenvironmentwerenot overcome by Flu/Cy in patients receiving CAR T cell therapy for LBCL [20].”
BackgroundSelf-citationMDSCs and T cells in solid tumors and non-Hodgkin lymphomas: an immunosuppressive speech
Cioccarelli, C., & Molon, B. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac025 · Cited by 11
Xierenguli, A., Zhang, J., Pang, N., Zhang, R., Chen, R., Zeng, X., Tudahong, S., Chen, G., Muhashi, M., Zhao, F., et al. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.853 · Cited by 10
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
Testa, U., Castelli, G., Leone, G. G. M., Pelosi, E., Castelli, G., & Hohaus, S. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.066 · Cited by 12
“17 Finally, a fourth study provided evidence that tumor immune contexture is a major determinant of Axi-Cel efficacy.”
BackgroundTumour Escape from CAR-T Cells
Rasche, L., Vago, L., & Mutis, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0_4 · Cited by 11
Kato, K., Fujii, N., Makita, S., Goto, H., Kanda, J., Shimada, K., Akashi, K., Izutsu, K., Teshima, T., Fukuda, N., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03494-7 · Cited by 9
Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation
Blanco, B., Mfarrej, B. G., LU, H., Irwin, L., Salmon, J., Morris, D., & Bowden, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.045 · Cited by 15
“23,30 Proactive use of anti-inflammatory agents, such as tocilizumab, has been shown to restore T cell expansion while maintaining manufacturing timelines.”
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
Perrone, S., Lopedote, P., Sanctis, V. D., Cumis, I. I. D., Pulsoni, A., & Strati, P. (2023) · Cancers · doi:10.3390/cancers15102751 · Cited by 9
“However, mere dimensional decrease is not sufficient, as residual disease can still be enriched with pro-tumoral myeloid cells that are responsible for the suppression of CAR T-cell amplification and function [87,88].”
BackgroundTrono, P., Tocci, A., Palermo, B., Carlo, A. D., D’Ambrosio, L., D’Andrea, D., Modugno, F. D., Nicola, F. D., Goeman, F., Corleone, G., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006913 · Cited by 9
Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
Gong, I. Y., Tran, D., Saibil, S. D., Laister, R. C., & Kuruvilla, J. G. (2024) · HemaSphere · doi:10.1002/hem3.130 · Cited by 10
“37,43,56,63,136 Given the now well ‐ established relationship between metabolism and T cell function, metabolomic analyses offer a potentially rich source of information on immune function.”
BackgroundApplications of single‐cell omics for chimeric antigen receptor T cell therapy
Ghaffari, S., Saleh, M., Akbari, B., Ramezani, F. M., & Mirzaei, H. R. (2023) · Immunology · doi:10.1111/imm.13720 · Cited by 10
Allogeneic and other innovative chimeric antigen receptor platforms
Jallouk, A. P., Sengsayadeth, S. M., Savani, B. N., Dholaria, B., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.121404 · Cited by 9
Facts and Hopes of Chimeric Antigen Receptor–Redirected NK T Cells
Courtney, A. N., Zhou, X., Tian, G., Wang, Y., Metelitsa, L. S., & Dotti, G. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0197 · Cited by 9
Ong, S. Y., Chen, Y., Tan, M. S. Y., Ho, A. Y. L., Hwang, W. Y. K., & Lim, F. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13964 · Cited by 7
Tang, D., Zhao, L., Yan, F., Ren, C., Xu, K., & Zhao, K. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008364 · Cited by 8
Lepik, K. V., & Витальевич, М. В. (2025) · Cancers · doi:10.3390/cancers17020317 · Cited by 10
Tumor microenvironment in CAR-T cell therapy for lymphoma
Zhu, Y., Xu, K., & Wang, Y. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101635 · Cited by 7
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7
“Tumor interferon signaling, high number of monocytic myeloid‐derived suppressor cells (M‐MDSCs), and elevated serum IL‐6 and ferritin all reduce the odds of durable response.(66) Tumor indoleamine 2,3‐ dioxygenase, which intracellularly converts tryptophan into metabolites that counteract T‐cell activity, also inhibit…”
BackgroundCao, B., Patel, K., Li, T., Yao, S., Chung, C. H., & Wang, X. (2022) · iScience · doi:10.1016/j.isci.2022.105915 · Cited by 7
“RS), has been proposed as a more effective prognostic signature and potential biomarker for immunotherapies.(20,21) Same as hypoxia signatures, it is unclear whether these IFN signatures and their subsets are generalizable across different cancer types.”
BackgroundSelf-citationConnarn, J. N., Witjes, H., Geffen, M. V. Z., de Greef, R., Campbell, T., Hege, K. M., Zhou, S. Y., & Lamba, M. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12922 · Cited by 7
“33 The final CRS requiring tocilizumab and CRS requiring steroids models were described using a sigmoid E max model and linear model, respectively.”
MethodASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
Strati, P., Pasvolsky, O., Feng, L., Xu, G., Tewari, S. O., Varghese, J., Ow, K., Santiago, M., Zaki, A. A., Jallouk, A. P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009622 · Cited by 7
“In fact, higher numbers of tissue macrophages with upregulated interferon signaling were associated with lower peak CAR T-cell expansion and worse outcomes in patients with LBCL treated with CART.13,14 In addition, polymorphisms in genes crucial for macrophage activation correlated with suboptimal response to conditio…”
BackgroundInfluentialFacts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Hijazi, A., Locke, F. L., Scholler, N., Mattie, M., Filosto, S., Bedognetti, D., & Galon, J. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2267 · Cited by 6
“Key factors associated with efficacy include systemic inflammation (24), tumor burden (24, 49), and the tumor immune microenvironment (25, 26, 50, 51), which collectively contribute to treatment resistance (25, 48, 52).”
Self-citationBlood proteomics for quantitative biomarkers of cellular therapies
Gafken, P. R., & Paczesny, S. (2025) · Biomarker Research · doi:10.1186/s40364-025-00837-4 · Cited by 6
“Parameters from the tumor microenvironment are also emerging as critical, for example high IFN signaling and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment is associated with poor CART cells expansion [99].”
Balke‐Want, H., Gödel, P., Schmid, C., Ayuk, F. A., Friedrichs, B., van Heteren, P., Holtkamp, S., Zadoyan, G., Brillant, C., Costa, J., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018073 · Cited by 6
“…to anti-CD19 CAR T cells has been attributed to several factors: limited CAR T-cell activity due to T-cell exhaustion, 4 accompanied by poor persistence, 5 as well as tumor-driven mechanisms such as an immunosuppressive microenvironment 6-9 and downregulation or even loss of the target antigen.”
Jin, J., Liu, T., Cheng, J., Meng, J., Wang, N., Huang, L., Zhou, X., Chen, L., Luo, H., & Zhou, J. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03418-2 · Cited by 6
“The former includes suppressive immune cells like MDSC [21] and TAM [20] and cytokines/ chemokines such as MCP-1 and IL-7 [13], and the latter involves immuno-phenotypes of CAR-T cells, such as the percentage of less differentiated T cell subsets [12] and the persistence of CAR-T cells in vivo [15].”
BackgroundMechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
Johnson, G. A., & Locke, F. L. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.07.003 · Cited by 7
Self-citationFoureau, D., Guo, F., Steuerwald, N., Druhan, L. J., Avalos, B. R., Copelan, E. A., Sun, D., Hu, B., Moyo, T. K., Jacobs, R. W., et al. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.10.004 · Cited by 7
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Zhang, X., Xu, K., Gale, R. P., & Pan, B. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02463-4 · Cited by 6
“Large mass of lymphoma cells can generate an immune suppressive intra-lymphoma microenvironment containing large numbers of immune suppressive ligands, cytokines and cells [42 – 44].”
Corona, M., Ip, A., Brown, S., Luna, A., Khatib, H. A., Flynn, J. R., Devlin, S. M., Landego, I., Cassanello, G., Rejeski, K., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02519-z · Cited by 9
Burleigh, K., Stratton, K. G., Smith, J. L., Jensen, M. C., Turtle, C. J., Keenan, C., Annesley, C., Summers, C. N., Webb‐Robertson, B., Hirayama, A. V. V., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.05.003 · Cited by 7
Treating CAR-T relapses: check not checkmate
Spiegel, J. Y., & Komanduri, K. V. (2022) · Blood · doi:10.1182/blood.2021013896 · Cited by 6
Lüönd, F., Whalen, J., Song, Y., Schriefer, K., Newcombe, R., Orlando, E. J., Choi, S. M., Ruella, M., Fraietta, J. A., Schuster, S. J., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0176 · Cited by 8
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma
Lue, J. K., Healton, S. E., & Salles, G. A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.06.013 · Cited by 5
Dodero, A., Ceparano, G., Casadei, B., Angelillo, P., Bramanti, S., Tisi, M. C., Ljevar, S., Stella, F., Chiappella, A., Botto, B., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016117 · Cited by 6
“In agreement with Jain et al, 19 our study showed an increase in cumulative NRM over time, increasing from 4.1% and 4.9% at 12 months to 10% and 11% at 24 months in HGBL and DLBCL, respectively, without any significant difference between the 2 histotypes.”
InfluentialArena, G., & Chiarle, R. (2025) · Cancers · doi:10.3390/cancers17213453 · Cited by 6
“Jain et al. demonstrated that patients with LBCL who did not achieve durable remission after Axicab-tagene ciloleucel had significant expression of interferon signaling, higher prevalence of MDSCs, and increased IL-6 and ferritin levels [74].”
InfluentialBiomarker-empowered precision navigation of CAR-T cell therapy
Wang, Y., Cheng, W., Kang, K., Niu, T., Zhao, A., & Wu, Y. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02647-0 · Cited by 5
“Consistently, high expression of macrophage-related genes (CD163, Siglec-1) in the TME is associated with the lack of durable response to CAR-T therapy, and their expression shows a strong positive correlation with tumor interferon signaling genes [91].”
InfluentialThe Bidirectional Interplay between T Cell–Based Immunotherapies and the Tumor Microenvironment
Pherez-Farah, A., Boncompagni, G., Chudnovskiy, A., & Pasqual, G. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0857 · Cited by 6
“Supporting this, Jain and colleagues (52) found that the IFN signaling, which is enriched in patients with nondurable responses to CD19 CAR T cells, had a strong correlation with macrophages, neutrophils, and DCs but not Tregs.”
Yun, K., Sakemura, R. L., Can, İ., Ruiz, O. L. G., Ogbodo, E. J., Zhang, S., Saleh, A., Huynh, T. N., Roman, C. M., Sirpilla, O. L., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200985 · Cited by 8
Interleukin-4 modulates type I interferon to augment antitumor immunity
Newnes, H. V., Armitage, J. D., Buzzai, A. C., de Jong, E., Audsley, K. M., Barnes, S. A., Srinivasan, S., Serralha, M., Fear, V. S., Guo, B. B., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt3618 · Cited by 7
“However, recent studies have highlighted that a highly inflammatory and IFN-I–skewed TME showed resistance to therapy and worse patient outcomes ( 21 , 22 ).”
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy
Zaki, A. A., McCurry, D., & Strati, P. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2185090 · Cited by 5
“Elevated blood levels of circulating myeloid-derived suppressor cells as well as pretreatment biopsy specimens with baseline tumor inflammation characterized by high levels of interferon signaling was associated with lower peak CAR T-cell expansion and worse outcomes in LBCL patients treated with axi-cel [26].”
BackgroundInfluentialCAR T-cell hematotoxicity: is inflammation the key?
Faramand, R. G., & Davila, M. L. (2021) · Blood · doi:10.1182/blood.2021012876 · Cited by 5
“the rates of severe toxicities in high-risk patients.(4,7) Moreover, identifying “lowrisk” patients who may be safely treated as outpatients is important.”
BackgroundMethodSelf-citationQiu, J., Ye, D., Chen, X. E., Dangle, N. J., Yoshor, B., Zhang, T., Shao, Y., Nallamala, V. C., Wang, S., Ren, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.13.607862 · Cited by 5
Ceballos, C., Viguria, M. C., Panizo, C., Rodríguez-Madoz, J. R., & Prósper, F. (2023) · Frontiers in Hematology · doi:10.3389/frhem.2023.1217775 · Cited by 5
Poddar, S., Yan, J., Tiwari, G., Rinchai, D., Budka, J. A., Zhang, W., Peng, W., Salunkhe, S., Davis, M. J., Song, Q., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181893 · Cited by 6
Gurevich‐Shapiro, A., Zwicky, P., Winter, E. E., Zada, M., Shapira, N., Barboy, O., Chalan, P., Sharet-Eshed, R., Kedmi, M., Ingelfinger, F., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-3596 · Cited by 5
Newnes, H. V., Armitage, J. D., Audsley, K. M., Bosco, A., & Waithman, J. C. (2021) · Cancers · doi:10.3390/cancers13235911 · Cited by 5
Tian, Y., Budka, J. A., Locke, F. L., Westin, J. R., To, C. A., Tiwari, G., Mao, D., Bedognetti, D., Shen, R. R., Andrade, J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1519473 · Cited by 5
“These fi ndings corroborate that the 6-GES and 17-GES are likely representative of response and resistance mechanisms and further support previous observations (9) that the TME and the biomarkers associated with outcome can change through lines of therapy.”
Self-citationVarela, V. A., Heinen, L. B. D. S., Marti, L. C., Caraciolo, V. B., Datoguia, T. S., Amano, M. T., & Pereira, W. O. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113441 · Cited by 6
Jallouk, A. P., Kui, N., Sun, R., Westin, J. R., Steiner, R. E., Nair, R. K., Nastoupil, L. J., Fayad, L., Zaki, A. A., Hawkins, M., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.284453 · Cited by 6
“4,15 Multiple mechanisms have been proposed to explain this association, including increased numbers of circulating MDSC and increased intra-tumoral expression of immune checkpoint ligands driven by inflammatory signaling pathways.”
BackgroundCancer immunotherapy by silencing transcription factor c-Rel using peptide-based nanoparticles
Lang, S., Zhu, Y., Tan, Z., Zhang, Y. X., Liang, R., Ren, J., Li, P., Pan, F., Cai, L., & Chen, Y. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1554496 · Cited by 4
Strati, P., Brandt, A. C., Lionel, A. C., Henderson, J. M., Westin, J. R., Adkins, S., Shpall, E. J., Kebriaei, P., Ramdial, J., Saini, N. Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012401 · Cited by 4
“PS is the guarantor.”
Magno, G., Rejeski, K., Rappa, G. P., Stock, S., Holzem, A. M. E., Landwehr, M., Seib, M., Kutsch, N., Mammadova, J., Mayer, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017766 · Cited by 4
Wang, Z., Miao, L., & Wang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1698146 · Cited by 6
“For instance, MDSCs have been shown to impair the function and persistence of CAR-T cells (41).”
Management of relapsed/refractory DLBCL in the era of novel agents and new approaches
Gong, I. Y., & Kuruvilla, J. G. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2599994 · Cited by 4
Targeting persister cells: proactively overcoming therapy resistance in aggressive B cell lymphomas
Tao, J., Qiu, K., & Williams, M. E. (2026) · Trends in cancer · doi:10.1016/j.trecan.2025.12.007 · Cited by 3
Inoue, Y., Shimura, Y., Niiyama‐Uchibori, Y., Chinen, S., Nakamura, T., Okamoto, H., Fujino, T., Tsukamoto, T., Mizutani, S., & Kuroda, J. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153287 · Cited by 3
Hu, C., Zhang, H., Zhu, H., Fan, J., Chen, D., Zhu, S., Li, C., Sun, J., Chen, Y., Ren, J., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08656-7 · Cited by 3
Immune-based therapies in diffuse large B-cell lymphoma
McCurry, D., Flowers, C. R., & Bermack, C. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2230137 · Cited by 3
Immune checkpoint inhibition and CAR T-cells: no longer exhausted?
Minehart, J. C., & Chong, E. A. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.11.008 · Cited by 3
Cytokines and immune effector cell therapy
Haugh, A. M., & Frigault, M. J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101628 · Cited by 3
Mécanismes de résistance et d’échappement aux cellules CAR-T
Grinda, T., Brouard, J., Tran, D., & Rubio, M. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.09.002 · Cited by 3
Jain, M. D., Coney, P., & Locke, F. L. (2021) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_10 · Cited by 3
Self-citation
Metadata
- Authors
- Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., Cao, B., Chavez, J. C., Shah, B., Lazaryan, A., Nishihori, T., Hussaini, M., Gonzalez, R. J., Mullinax, J. E., Rodriguez, P. C., Conejo-Garcia, J. R., Anasetti, C., Davila, M. L., & Locke, F. L.
- Affiliations
- Department of Blood and Marrow Transplant and Cellular Immunotherapy,
- Department of Clinical Science,
- Department of Bioinformatics and Biostatistics,
- Department of Malignant Hematology,
- Department of Pathology,
- Department of Sarcoma, and
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Tampa, FL
- University of South Florida (US)
- Corresponding author
- Jain, Michael D.
- Zhao, Hua
- ORCID
- Jain, Michael D.
- Zhao, Hua
- Wang, Xuefeng
- Atkins, Reginald
- Menges, Meghan
- Reid, Kayla
- Faramand, Rawan
- Bachmeier, Christina
- Dean, Erin A.
- Cao, Biwei
- Shah, Bijal
- Lazaryan, Aleksandr
- Nishihori, Taiga
- Gonzalez, Ricardo J.
- Mullinax, John E.
- Rodriguez, Paulo C.
- Conejo-Garcia, Jose R.
- Anasetti, Claudio
- Davila, Marco L.
- Locke, Frederick L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2021-05-13
- Volume
- 137
- Issue
- 19
- Pages
- 2621-2633
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC8120145
- OpenAlex
- W3123125599
- Semantic Scholar
- be4a1f2554f696107aa788eb12aaa850563c1cf0
- Cited by
- 297
- References
- 60
- Citations by year
- 2026: 40 · 2025: 63 · 2024: 54 · 2023: 72 · 2022: 43 · 2021: 23
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA184185, K23CA201594, P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- large B-cell lymphoma, axicabtagene ciloleucel, CAR T-cell therapy, treatment failure, interferon signaling, myeloid-derived suppressor cells, immune checkpoint ligands, PD-L1, interleukin-6, ferritin, immune dysregulation, CAR-T cell expansion, tumor burden, relapsed/refractory lymphoma
- MeSH terms
- Myeloid-Derived Suppressor Cells, Receptors, Chimeric Antigen, Adult, Aged, Biological Products, Female, Ferritins, Humans, Interferons, Male, Middle Aged, RNA, Neoplasm, Cytokines, Immunotherapy, Adoptive, Lymphoma, B-Cell, Treatment Failure, Tumor Escape, Tumor Burden, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.